A Prospective, Multi-Center, Randomized, Double-Masked, Positive Controlled, Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared to Prednisolone Acetate Ophthalmic Suspension (1%) in Patients With Non-Infectious Anterior Segment Uveitis

Trial Profile

A Prospective, Multi-Center, Randomized, Double-Masked, Positive Controlled, Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared to Prednisolone Acetate Ophthalmic Suspension (1%) in Patients With Non-Infectious Anterior Segment Uveitis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2018

At a glance

  • Drugs Dexamethasone (Primary) ; Prednisolone acetate
  • Indications Anterior uveitis
  • Focus Registrational; Therapeutic Use
  • Sponsors EyeGate Pharma
  • Most Recent Events

    • 06 Apr 2018 Data from this trial will be used to support a New Drug Application (NDA) to the US FDA for EGP-437 which is expected in the first half of 2019.
    • 06 Apr 2018 Status changed from recruiting to active, no longer recruiting, as reported in an EyeGate Pharmaceuticals media release.
    • 02 Mar 2018 According to an EyeGate Pharmaceuticals media release, the data from this trial is expected in the third quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top